Invasive Candidiasis
Conditions
Interventions
L-AMB group The recommended dose is 2.5-5.0 mg/kg body weight administered intravenously over 1-3 hours once a day. Depending on the patient condition, the dose can be increased or decreased within
Sponsors
Department of Infection Control and Prevention, Aichi Medical University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient with Invasive Candidiasis or Suspected Invasive Candidiasis
Exclusion criteria
Exclusion criteria: (1) Cases treated with L-AMB or MCFG of those enrolled in this study. (2) Patients with a history of hypersensitivity to the ingredients of this product, such as shock (3) Children (younger than 16 years old) (4) Patients undergoing treatment (leukocyte transfusion) that is contraindicated for use in combination with L-AMB. (5)Pregnant or lactating patients or possibly pregnant patients. (6)Patients with a present illness of serious liver diseases not caused by infections or a past history of them. (7) Patients with neutrophil counts of <500 cells/mm3. (8)Patients with serious underlying diseases or infections who are not expected to live throughout the study period. (9) Other patients judged to be unsuitable as subjects by the physicians in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effect (efficacy ratio) at the end or discontinuation of administration Clinical symptoms between 4 and 7 days after the start of administration Clinical symptoms between 5 and 10 days after the end of administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Mycological effect Serological effect | — |
Countries
Japan
Contacts
Public ContactYuka Yamagishi
Aichi Medical University Hospital Department of Infection Control and Prevention
Outcome results
None listed